CD274 and triple-negative breast carcinoma: Taken together, human hepatocytes express PD-L1 and are likely targeted by the atezolizumab, although its expression level of PD-L1 is relatively low compared with that in triple-negative breast cancer (TNBC) cells, MDA-MB-231.